Abstract:Background. Liver fibrosis is the early pathological manifestation of various chronic liver diseases (including schistosomiasis, alcoholic, viral, nonalcoholic, fatty liver, etc.), which can progress to cirrhosis and even liver cancer. Out of the 7.7 billion world population, approximately 2 billion individuals have evidence of hepatitis B virus (HBV) infection; of these, 350 to 400 million suffer from chronic HBV infection, accounting for about 5% of the global population. The global prevalence of hepatitis C is 3%. These figures indicate that liver fibrosis is quite common. Methods. 98 patients with liver fibrosis were included in this study. The serum chitinase-3 Like Protein-1 (CHI3L1) level was measured by the double antibody Sandwich ELISA method. Results. Serum levels of CHI3L1 were significantly different between no-fibrosis and fibrosis groups (P < 0.01). There was a strong correlation between the levels of CHI3L1, elastometry, hyaluronan, CIV (P < 0.01) and age and sex, TBIL, DBIL, ALB, AST, ALT, GGT, ALP, PLT, LN, PIINP, FIB-4, and APRI (P < 0.05). The expression of CHI3L1 was different from fibrosis grades S1, S3, and S4 (P < 0.05, P < 0.001). The expression of CHI3L1 was significantly different between F1 and F4 (P < 0.05). Serum CHI3L1 expression level can be a valuable metric for diagnosing liver fibrosis, with an AUC value of 0.812. Out of the 98 patients who had undergone liver puncture, 79 patients (30.38%) had ALT <= 2ULN. Conclusions. The expression level of serum CHI3L1 was significantly higher in patients with liver fibrosis than that in patients without liver fibrosis. The expression levels of serum CHI3L1 were different in different grades of liver fibrosis and increased with the severity of liver fibrosis. Serum CHI3L1 can distinguish early stage (S1) of liver fibrosis from late stage (S3-4) of liver fibrosis. Serum CHI3L1 combined with HA is even more effective in the diagnosis of S2-4 hepatic fibrosis. The diagnostic efficacy of serum CHI3L1 in patients with ALT <= 2ULN was better than that of the other non-invasive diagnostic models.

A simple noninvasive index to predict significant liver fibrosis in patients with advanced schistosomiasis japonica.

The Diagnostic Value of the Fib-4 Index for Staging Hepatitis B-Related Fibrosis: A Meta-Analysis

Serum CHI3L1 As a Biomarker for Non-invasive Diagnosis of Liver Fibrosis.

A Novel Noninvasive Index for the Prediction of Moderate to Severe Fibrosis in Chronic Hepatitis B Patients

Determination of Serum Levels of YKL-40 and Hyaluronic Acid in Patients with Hepatic Fibrosis Due to Schistosomiasis Japonica and Appraisal of Their Clinical Value.

Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China

Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B.

Determination of Serum Fibrosis Indexes in Patients with Chronic Hepatitis and Its Significance

Establishment and Validation of a Simple Noninvasive Model to Predict Significant Liver Fibrosis in Patients with Chronic Hepatitis B

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

Real-time shear wave elastrography and APRI index for evaluating autoimmune hepatitis fibrosis

Staging of Liver Fibrosis in Chronic Hepatitis B Patients with A Composite Predictive Model: A Comparative Study

Noninvasive Indicators Predict Advanced Liver Fibrosis in Autoimmune Hepatitis Patients.

Development and validation of a noninvasive prediction model for significant hepatic liver fibrosis in Chinese patients with autoimmune hepatitis

Utility of real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C infection without cirrhosis: Comparison of liver fibrosis indices

Assessment of Noninvasive Diagnostic Models for Predicting Liver Fibrosis in Patients with Chronic Hepatitis B Virus Infection

Diagnostic Estimation of Noninvasive Tests for Hepatic Fibrosis in Chronic Hepatitis B Patients Without a Gold Standard

Evaluation of Noninvasive Diagnostic Models of Liver Fibrosis in Patients with Chronic Hepatitis B

Noninvasive Methods for Detecting Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B: A Single-Center Retrospective Study

Using blood routine indicators to establish a machine learning model for predicting liver fibrosis in patients with Schistosoma japonicum

Diagnostic efficacy of FibroScan for liver inflammation in patients with chronic hepatitis B: a single-center study with 1185 liver biopsies as controls